Literature DB >> 20421731

Rift Valley fever virus: an unrecognized emerging threat?

Robert B Mandell1, Ramon Flick.   

Abstract

Rift Valley fever virus (RVFV) is an arthropod-borne pathogen that often results in severe morbidity and mortality in both humans and livestock. As its geographic range continues to spread, it presents a real threat to naïve populations around the world by accidental introduction (e.g., the result of increased world travel) or a bioterror event. The lack of prophylactic and therapeutic measures, the potential for human-to-human transmission, and the significant threat to livestock associated with RVFV make infection with these pathogens a serious public health concern. Rift Valley fever epizootics and epidemics might rapidly overwhelm the capacities of the public health and veterinary medical communities to provide rapid diagnostic testing, distribution of countermeasures and adequate medical care.

Entities:  

Mesh:

Year:  2010        PMID: 20421731     DOI: 10.4161/hv.6.7.11761

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  14 in total

1.  Seroprevalence of Rift Valley Fever Virus Antibodies in Cattle in Mali, 2005-2014.

Authors:  Sonu Subudhi; Martin Dakouo; Angela Sloan; Derek R Stein; Allen Grolla; Shane Jones; Antonia Dibernardo; Kyle Rosenke; Miriam Sas; Abdalah Traore; Robbin Lindsay; Martin H Groschup; Vikram Misra; Heinz Feldmann; Nafomon Sogoba; David Safronetz; Mamadou Niang
Journal:  Am J Trop Med Hyg       Date:  2018-01-18       Impact factor: 2.345

2.  Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Authors:  Nandadeva Lokugamage; Alexander N Freiberg; John C Morrill; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

3.  Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKR.

Authors:  Birte Kalveram; Olga Lihoradova; Sabarish V Indran; Nandadeva Lokugamage; Jennifer A Head; Tetsuro Ikegami
Journal:  Virology       Date:  2012-10-12       Impact factor: 3.616

4.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

5.  Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Authors:  Phillip R Pittman; Sarah L Norris; Elizabeth S Brown; Manmohan V Ranadive; Barbara A Schibly; George E Bettinger; Nandadeva Lokugamage; Lawrence Korman; John C Morrill; Clarence J Peters
Journal:  Vaccine       Date:  2015-12-17       Impact factor: 3.641

6.  The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine.

Authors:  Olga Lihoradova; Birte Kalveram; Sabarish V Indran; Nandadeva Lokugamage; Terry L Juelich; Terence E Hill; Chien-Te K Tseng; Bin Gong; Shuetsu Fukushi; Shigeru Morikawa; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

7.  Functional analysis of Rift Valley fever virus NSs encoding a partial truncation.

Authors:  Jennifer A Head; Birte Kalveram; Tetsuro Ikegami
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 8.  The risk of Rift Valley fever virus introduction and establishment in the United States and European Union.

Authors:  Alicia I Rolin; Lea Berrang-Ford; Manisha A Kulkarni
Journal:  Emerg Microbes Infect       Date:  2013-12-04       Impact factor: 7.163

9.  Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals.

Authors:  Sean Broce; Lisa Hensley; Tomoharu Sato; Joshua Lehrer-Graiwer; Christian Essrich; Katie J Edwards; Jacqueline Pajda; Christopher J Davis; Rami Bhadresh; Clarence R Hurt; Beverly Freeman; Vishwanath R Lingappa; Colm A Kelleher; Marcela V Karpuj
Journal:  Biol Direct       Date:  2016-05-14       Impact factor: 4.540

10.  Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United States.

Authors:  Andrew J Golnar; Michael J Turell; A Desiree LaBeaud; Rebekah C Kading; Gabriel L Hamer
Journal:  PLoS Negl Trop Dis       Date:  2014-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.